Statements (26)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Arthur_T._Sands
|
| gptkbp:collaboratedWith |
gptkb:Sanofi
gptkb:Gilead_Sciences |
| gptkbp:developedBy |
NX-2127
NX-0479 NX-1607 NX-5948 |
| gptkbp:focusesOn |
drug discovery
targeted protein degradation E3 ligase modulation protein modulation |
| gptkbp:foundedBy |
gptkb:John_Kuriyan
gptkb:Craig_Crews gptkb:Michelle_Arkin Ray Deshaies |
| gptkbp:foundedYear |
2012
|
| gptkbp:headquartersLocation |
gptkb:San_Francisco,_California,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Nurix Therapeutics
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:publiclyTraded |
true
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
NRIX
|
| gptkbp:website |
https://www.nurixtx.com/
|
| gptkbp:bfsParent |
gptkb:The_Column_Group
|
| gptkbp:bfsLayer |
7
|